Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SenesTech, Inc. (SNES)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.0400+0.0400 (+1.33%)
At close: 03:59PM EST
3.0800 +0.04 (+1.32%)
After hours: 05:07PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.0000
Open2.9301
Bid2.8400 x 900
Ask3.2500 x 1000
Day's Range2.9000 - 3.5100
52 Week Range1.6000 - 23.2000
Volume66,083
Avg. Volume99,659
Market Cap37.11M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-2.7850
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • American City Business Journals

    Phoenix pest-control company SenesTech names industry veteran as CEO

    Nearly a year after the Phoenix company introduced its flagship birth control for rats product, the company is looking to a new CEO to guide its commercialization.

  • PR Newswire

    SenesTech, Inc. Announces Closing of $5 Million Public Offering

    SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company") (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the closing of its previously announced public offering of 1,428,572 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 1,428,572 shares of its common stock ("Series A Warrants"), and Series B warrants to purchase up t

  • PR Newswire

    SenesTech, Inc. Announces Pricing of $5 Million Public Offering

    SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company") (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced the pricing of a public offering of up to 1,428,572 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 1,428,572 shares of its common stock ("Series A Warrants"), and Series B warrants to purchase up to 1,428,572 share

Advertisement
Advertisement